Background: Dual-task walking is used as a treatment, for gait assessment, and as an outcome measure in Parkinson's disease (PD). Movement smoothness, i.e. its non-intermittency, is a movement cardinal feature. This study assesses whether dual-tasking reduces gait smoothness in PD alongside reducing speed, one of its well-known effects.
Methods: The Timed Up and Go (TUG) test, instrumented with an inertial sensor fixed to the back, was administered to 33 PD patients (15 females; age: median = 71 years; IQR = 10) to assess two walking types: straight-walking and turning-while-walking. The TUG test was completed in single-task and two dual-task modalities: cognitive (doing successive subtractions) and motor (holding a water glass). The angular speed spectral arc length metric (SPARC) and the Ln-DimensionLess Jerk (LDLJ), two smoothness measures quantifying the peaks and dips in the speed profile, were measured, along with the trunk angular velocity and the foot strikes number. ANOVA was used for hypothesis testing and estimated marginal means for post-hoc tests and effect sizes (ES).
Results: In straight-walking and turning, cognitive and motor dual tasks decreased gait speed (ES range = [0.476, 1.379]; p < 0.01) and increased the step number (ES = [0.402, 0.927]; p < 0.05). SPARC (ES = [0.221, 0.493]; p < 0.05) and angular LDLJ (ES = [0.451, 0.929]; p < 0.01) were lower in the two dual-task conditions in both phases, indicating reduced gait smoothness than in single-task. This worsening of gait smoothness was partially confirmed after ruling out the dual-task effect on speed and step number. In particular, anterior-posterior SPARC during turning was still low in cognitive (ES = 0.351; p < 0.01) and motor (ES = 0.283; p < 0.05) dual tasks.
Conclusions: In PD, dual-tasking decreases gait speed and increases the step number when walking straight and turning while walking. Independently of these effects, dual-tasking also reduces gait smoothness. As an independent feature of movement, when dual-task walking is the outcome measure, improving smoothness may represent a novel treatment aim in PD. As long as it is instrumented with an inertial sensor, the TUG test is valuable for studying different walking types.
Trial Registration: NCT05904171 (ClinicalTrials.gov; date registration: 2023-06-06).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887220 | PMC |
http://dx.doi.org/10.1186/s13102-025-01068-8 | DOI Listing |
Cells
February 2025
Department of Biochemistry and Molecular Biology and Physiology, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain.
Neurodegenerative diseases encompass a number of very heterogeneous disorders, primarily characterized by neuronal loss and a concomitant decline in neurological function. Examples of this type of clinical condition are Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and Amyotrophic Lateral Sclerosis. Age has been identified as a major risk in the etiology of these disorders, which explains their increased incidence in developed countries.
View Article and Find Full Text PDFCells
February 2025
Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.
Parkinson's disease (PD) represents a growing challenge to global health, as it involves millions of people. The high grade of disability is due to the loss of dopaminergic neuron activity, and levodopa is the gold-standard therapy used to restore dopamine in the dopamine-denervated regions. Another therapeutic approach is the use of A adenosine receptor antagonists and, among them, istradefylline is the only one currently approved for therapy in association with levodopa.
View Article and Find Full Text PDFAdv Biol (Weinh)
March 2025
Medizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, 44801, Bochum, Germany.
Aging is a progressive and irreversible process, serving as the primary risk factor for neurodegenerative disorders. This study aims to identify the molecular mechanisms underlying physiological aging within the substantia nigra, which is primarily affected by Parkinson's disease, and to draw potential conclusions on the earliest events leading to neurodegeneration in this specific brain region. The characterization of essential stages in aging progress can enhance knowledge of the mechanisms that promote the development of Parkinson's disease.
View Article and Find Full Text PDFStem Cells
March 2025
Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.
Cell replacement therapies using human pluripotent stem cell-derived ventral midbrain (VM) dopaminergic (DA) progenitors are currently in clinical trials for treatment of Parkinson's disease (PD). Recapitulating developmental patterning cues, such as fibroblast growth factor 8 (FGF8), secreted at the midbrain-hindbrain boundary (MHB), is critical for the in vitro production of authentic VM DA progenitors. Here, we explored the application of alternative MHB-secreted FGF-family members, FGF17 and FGF18, for VM DA progenitor patterning.
View Article and Find Full Text PDFInt Clin Psychopharmacol
March 2025
Oasi Research Institute - IRCCS, Troina, Italy.
Depression is a common comorbidity in Parkinson's disease (PD), significantly reducing patients' quality of life. This mini-review examines pharmacological and nonpharmacological therapies for managing depression in PD, analyzing their benefits, and limitations. Pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), levodopa, dopaminergic agonists, and monoamine oxidase B inhibitors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!